AN ECONOMIC EVALUATION OF CABOZANTINIB VS. EVEROLIMUS IN THE SECOND-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA

被引：0
|
作者：
Hart, L. A. [1 ]
Carlson, J. J. [1 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN135
引用
收藏
页码：A111 / A111
页数：1
相关论文
共 50 条
  • [1] ECONOMIC EVALUATION OF EVEROLIMUS AS SECOND-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN GREECE
    Solakidi, A.
    Kourlaba, G.
    Kontovinis, L.
    Koutsoukos, K.
    Bournakis, E.
    Boutis, A.
    Syrios, J.
    Tzovaras, A.
    Michailidi, C.
    Kalogeropoulou, M.
    Maniadakis, N.
    VALUE IN HEALTH, 2016, 19 (07) : A732 - A732
  • [2] Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma
    Alesini, Daniele
    Mosillo, Claudia
    Naso, Giuseppe
    Cortesi, Enrico
    Iacovelli, Roberto
    THERAPEUTIC ADVANCES IN UROLOGY, 2015, 7 (05) : 286 - 294
  • [3] Advanced Renal Cell Carcinoma Cabozantinib Monotherapy is the Second-line Therapy Standard
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (11) : 638 - 639
  • [4] Second-line everolimus treatment in advanced renal-cell cancer
    Brower, Vicki
    LANCET ONCOLOGY, 2012, 13 (06): : E235 - E235
  • [5] Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison
    Porta, Camillo
    Szczylik, Cezary
    Casciano, Roman
    Fu, Shuai
    Amzal, Billy
    Lister, Johanna
    Karcher, Helene
    Meng, Jie
    Neumann, Monika
    Dinet, Jerome
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 139 : 143 - 148
  • [6] Comparative clinical and economic analysis of using cabozantinib as second-line therapy for adult patients with advanced renal cell carcinoma
    Krysanov, I. S.
    Krysanova, V. S.
    Alekseev, B. Ya
    Ermakova, V. Yu
    Gameeva, E., V
    ONKOUROLOGIYA, 2020, 16 (02): : 52 - 64
  • [7] Advanced Renal Cell Carcinoma Lenvatinib in Combination with Everolimus is approved as a Second-line Therapy
    Krampe-Scheidler, Anne
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (10) : 666 - 667
  • [8] Economic Evaluation of Nivolumab as a Second-Line Treatment for Advanced Renal Cell Carcinoma From US and Chinese Perspectives
    Wan, Xiao Min
    Peng, Liu Bao
    Ma, Jin An
    Li, Yuan Jian
    CANCER, 2017, 123 (14) : 2634 - 2641
  • [9] Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2018, 7 (02) : 123 - 133
  • [10] Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma
    Soto-Perez-de-Celis, Enrique
    Aguiar, Pedro N., Jr.
    Cordon, Monica L.
    Chavarri-Guerra, Yanin
    Lopes, Gilberto de Lima, Jr.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (06): : 669 - 675
12345